How Drug Price Reform Will Affect Specialty Pharmacy

Doug Long, vice president of Industry Relations at IQVIA, discusses rebate reform surrounding Medicare Part D and Part B in an interview with Specialty Pharmacy Times.

Doug Long, vice president of Industry Relations at IQVIA, discusses rebate reform surrounding Medicare Part D and Part B in an interview with Specialty Pharmacy Times.

Transcript

It's unknown, because we were going to do rebate reform on Medicare Part D, but ultimately, they decided to go with reference pricing on Medicare Part B, which I think will have a big impact on Medicare Part B drugs. We'll see how that goes, the Senate just proposed some things that I haven't had a chance to look out. I know it's a top priority for President Trump to show progress on prescription drugs. The challenge is that there are $166 billion of rebates in the system. A lot of those go to the government, a lot of that goes to sponsors, and nobody wants to really give them up. So, we'll have to see on that one as well.